NextCure Inc
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland. Show More...
-
Website https://www.nextcure.com
-
Sector Healthcare
-
Industry Biotechnology
-
Last Quote 0.49 USD
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share USD -1.54 -2.27 -2.15 -0.65 Dividends USD Payout Ratio % * Shares Mil 10.0 10.0 16.0 28.0 Book Value Per Share * USD 6.21 12.06 Free Cash Flow Per Share * USD -0.34 Return on Assets % -79.46 -27.29 -13.39 -7.3 Financial Leverage (Average) 1.11 1.04 Return on Equity % -24.58 -12.79 Return on Invested Capital % -24.1 -12.36 Interest Coverage Current Ratio 3.02 13.19 22.6 40.07 Quick Ratio 2.7 13.13 22.24 39.51 Debt/Equity 0.010 0.010